Life sciences

Straightforward, business-friendly advice from lawyers who understand the unique challenges and opportunities presented by the life sciences sector.  We enjoy spending time getting to know our clients and working alongside them for the long term. Visit our life sciences hub
  • Profile
  • Key contacts

We work with a wide range of clients from the life sciences sector including:

  • pharmaceutical companies
  • biotechnology companies
  • medical device and diagnostic companies
  • manufacturers, distributors and logistics companies
  • investors
  • banks and financial institutions. 

"The entire group is outstanding. They are always extremely quick, up to speed and ready to build a tailor-made team according to the case at hand. We appreciate their excellent understanding of the industry."

The Legal 500 UK 2024

Latest news & insights

10 May 2024

From Insights

AI update – the regulatory approach to AI and medical products in the UK

The Medicines and Healthcare products Regulatory Agency (MHRA), has published a report on the Impact of AI on the Regulation of Medical Products in response to the gov..

More

25 Apr 2024

From News

Stephenson Harwood promotes eight to partnership

Law firm Stephenson Harwood LLP has promoted eight lawyers to its partnership, effective from 1 May 2024.

More

07 Mar 2024

From News

Stephenson Harwood advises Hong Kong AI business on reverse merger and NASDAQ listing

Stephenson Harwood's Hong Kong corporate team has advised YOOV Group on its proposed reverse merger and listing on NASDAQ.

More

29 Feb 2024

From Insights

Life sciences A to Z – L is for Leasing in life sciences

Given the activities and operations of life sciences companies, their property requirements will differ from companies in more mainstream sectors.

More

07 Feb 2024

From News

Stephenson Harwood advises on healthcare data acquisition

Stephenson Harwood LLP has acted for FPE Capital LLP on the acquisition by its portfolio company, Egress, of healthcare data migration specialist Stalis.

More

31 Jan 2024

From News

Stephenson Harwood advises Lansen Pharmaceutical on privatisation

Stephenson Harwood LLP acted as the Hong Kong legal adviser to Lansen Pharmaceutical Holdings Limited (Lansen Pharmaceutical) on its privatisation by Cathay Internatio..

More

25 Jan 2024

From Insights

Life sciences A to Z - JK is for JPM: what to Know

The 42nd J.P. Morgan Healthcare Conference took place in San Francisco during the second week of January.

More

20 Nov 2023

From News

Stephenson Harwood advises on $25 million funding in ViaNautis Bio

Stephenson Harwood LLP has advised UCB Ventures, BGF and 4Bio Capital, who led the over-subscribed Series A funding round of $25million in ViaNautis Bio.

More

13 Oct 2023

From News

Stephenson Harwood advises DMS Group on SFT Acquisition

Law firm Stephenson Harwood LLP has advised DMS Group, a Euronext Growth Paris listed company, on its acquisition of Solutions For Tomorrow (SFT).

More

20 Sep 2023

From News

Stephenson Harwood advises BenevolentAI on strategic collaboration with Merck

Law firm Stephenson Harwood LLP has advised BenevolentAI on its recent strategic collaboration with Merck.

More

13 Sep 2023

From News

Stephenson Harwood advises Novacyt on Yourgene Health takeover

Law firm Stephenson Harwood LLP has advised long-standing diagnostics client Novacyt S.A. in relation to its recommended takeover of Yourgene Health plc

More

05 Sep 2023

From News

Stephenson Harwood advises Flarin on fundraise

Law firm Stephenson Harwood LLP has advised Flarin, the joint pain relief brand, on its fundraise through existing investor IW Capital and through ITV's Media for Equi..

More

01 Aug 2023

From Insights

Life sciences A to Z - J is for jumping the gun

Illumina pays record fine for pre-emptive GRAIL merger completion

More

12 Jul 2023

From Insights

Life sciences A to Z - I is for investment allocation

On the evening of Monday 10 July the Rt Hon Jeremy Hunt delivered his first Mansion House speech as the UK Chancellor of the Exchequer. A key element of the speech was..

More

15 May 2023

From News

Stephenson Harwood advises Bicycle Therapeutics on radiotherapy deal with Bayer

Law firm Stephenson Harwood LLP has advised Bicycle Therapeutics plc on its recent strategic collaboration agreement with Bayer to discover and develop Bicycle radioco..

More

11 Apr 2023

From Insights

Time to reap the benefits? The UK's new subsidy control regime comes into effect

On 4 January 2023, the UK's new post-Brexit subsidy control regime officially came into force, in the form of the Subsidy Control Act 2022 ("SCA").

More

print-footer
logo
© Stephenson Harwood LLP 2016. Any reference to Stephenson Harwood in this document means Stephenson Harwood LLP and/or its affiliated undertakings. Any reference to a partner is used to refer to a member of Stephenson Harwood LLP.